DSIP (Delta Sleep-Inducing Peptide)

DSIP Regulatory Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

DSIP holds no marketing authorisation from the MHRA, EMA or FDA and has not been through regulatory review in any jurisdiction. It carries an International Nonproprietary Name, emideltide, which reflects a WHO naming decision rather than any assessment of safety or efficacy.

Key facts

MHRA status
Not authorised
EMA status
Not authorised
FDA status
Not approved
INN
Emideltide, a naming decision only
UK supply basis
Laboratory research only
Claimed indication
None may be claimed

What an INN is and is not

An International Nonproprietary Name is assigned by the WHO so a substance has one unambiguous generic name worldwide. Assignment happens on request and reflects a need to identify the compound consistently. It says nothing whatsoever about safety, efficacy or approval, and a compound can hold an INN indefinitely without ever being authorised anywhere. DSIP's INN is emideltide.

Why this compound needs the point made clearly

DSIP is unusual among research peptides in carrying a name that asserts a therapeutic effect. A compound called delta sleep-inducing peptide, holding an INN, reads as though it were a medicine at some stage of development. It is not. The name records a 1977 hypothesis, the INN records a naming request, and neither records an assessment by anyone.

Research material referenced

DSIP 5mg, third-party HPLC tested

Buy DSIP · £13.95

The claim we do not make

We do not say DSIP induces sleep, improves sleep, or affects sleep in any person. The published basis for such a claim is an EEG observation in rabbits from 1977, with no receptor, no gene and no confirmed mechanism behind it. Making the claim would be inaccurate on the science before it was a problem under the UK framework, where a therapeutic claim about material supplied for research converts it into an unlicensed medicine.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated peptide products in April 2026. Sleep claims about a compound literally named for sleep are close to the top of the list of things that framework is concerned with, which is why this category is written the way it is.

What would change the position

A marketing authorisation following an application and assessment. For DSIP specifically that would first require the mechanistic groundwork the field never completed: a receptor, a mechanism, and controlled trials in humans. None of that exists.

Frequently asked questions

Does having an INN mean DSIP is a drug?

No. An INN is a naming decision by the WHO. It carries no assessment of safety or efficacy and no approval.

Why will you not describe DSIP's effects on sleep?

Because the evidence is a 1977 rabbit EEG observation with no established mechanism, and because a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More DSIP (Delta Sleep-Inducing Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.